Myeloproliferative neoplasm induced by constitutive expression of JAK2 V617F in knock-in mice

Blood

Volumn 116, Issue 5, 2010, Pages 783-787

  Marty, Caroline ^a,b,c   Lacout, Catherine ^a,b,c   Martin, Antoine ^a,b,c,d   Hasan, Salma ^a,b,c   Jacquot, Sylvie ^e   Birling, Marie Christine ^e   Vainchenker, William ^a,b,c   Villeval, Jean Luc ^a,b,c  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d AVICENNE HOSPITAL   (France)

^e INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROID PRECURSOR CELL; GENE MUTATION; GRANULOCYTOSIS; MOUSE; MYELOFIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; THROMBOCYTOSIS; AMINO ACID SUBSTITUTION; ANIMAL; C57BL MOUSE; CELL LINEAGE; CROSS BREEDING; ENZYMOLOGY; GENE TARGETING; GENETICS; HETEROZYGOTE; HUMAN; HYPERPLASIA; MISSENSE MUTATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHYSIOLOGY; POINT MUTATION; THROMBOCYTHEMIA; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; BONE MARROW; CELL LINEAGE; CROSSES, GENETIC; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; HUMANS; HYPERPLASIA; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SPLEEN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 77956280929     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-257063     Document Type: Article

References (13)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
4. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108(7):2435-2437.
5. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
6. Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
7. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66(23):11156- 11165. (Pubitemid 46009942)
8. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006;1e18.
9. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
10. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111(10):5109-5117.
11. Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
12. Dupont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013-1021.
13. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352.